Brenton Cavanagh

Dr. Brenton Cavanagh

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2011 in Molecules
Verified
Journal Article
Open access
PDF file
BCBrenton Cavanagh
Brenton Cavanagh
TWTom Walker
Tom Walker
ANAnwar Norazit
Anwar Norazit
AMAdrian C.B. Meedeniya
Adrian C.B. Meedeniya
Replicating cells undergo DNA synthesis in the highly regulated, S-phase of the cell cycle. Analogues of the pyrimidine deoxynucleoside thymidine may be inserted into replicating DNA, effectively tagging dividing cells allowing their characterisation. Tritiated thymidine, targeted using autoradiography was technically demanding and superseded by 5-bromo-2-deoxyuridine (BrdU) and related halogenated analogues, detected using antibodies. Their detection required the denaturation of DNA, often constraining the outcome of investigations. Despite these limitations BrdU alone has been used to target newly synthesised DNA in over 20,000 reviewed biomedical studies. A recent breakthrough in “tagging DNA synthesis” is the thymidine analogue 5-ethynyl-2′-deoxyuridine (EdU). The alkyne group in EdU is readily detected using a fluorescent azide probe and copper catalysis using ‘Huisgen’s reaction’ (1,3-dipolar cycloaddition or ‘click chemistry’). This rapid, two-step biolabelling approach allows the tagging and imaging of DNA within cells whilst preserving the structural and molecular integrity of the cells. The bio-orthogonal detection of EdU allows its application in more experimental assays than previously possible with other “unnatural bases”. These include physiological, anatomical and molecular biological experimentation in multiple fields including, stem cell research, cancer biology, and parasitology. The full potential of EdU and related molecules in biomedical research remains to be explored.

1 December 2017 in Biomaterials
Verified
Journal Article
Closed access
RRRosanne Raftery
Rosanne Raftery
ICIrene Mencía Castaño
Irene Mencía Castaño
GCGang Chen
Gang Chen
BCBrenton Cavanagh
Brenton Cavanagh
BQBrian Quinn
Brian Quinn
Fergal O'BrienFergal O'Brien
Fergal O'Brien

10 July 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
SDSukhraj Pal Singh Dhami
Sukhraj Pal Singh Dhami
SPSean Patmore
Sean Patmore
CCClaire Comerford
Claire Comerford
CBCiara M. Byrne
Ciara M. Byrne
BCBrenton Cavanagh
Brenton Cavanagh
JOJamie M. O'SUllivan
Jamie M. O'SUllivan
Breast cancer results in a three‐ to four‐fold increased risk of venous thromboembolism (VTE), which is associated with reduced patient survival. Despite this, the mechanisms underpinning breast cancer‐associated thrombosis remain poorly defined. Tumor cells can trigger endothelial cell (EC) activation resulting in increased von Willebrand factor (VWF) secretion. Importantly, elevated plasma VWF levels constitute an independent biomarker for VTE risk. Moreover, in a model of melanoma, treatment with low molecular weight heparin (LMWH) negatively regulated VWF secretion and attenuated tumor metastasis. To investigate the role of VWF in breast cancer metastasis and examine the effect of LMWH in modulating EC activation and breast tumor transmigration. von Willebrand factor levels were measured by ELISA. Primary ECs were used to assess tumor‐induced activation, angiogenesis, tumor adhesion, and transendothelial migration. Patients with metastatic breast cancer have markedly elevated plasma VWF:Ag levels that also correlate with poorer survival. MDA‐MB‐231 and MCF‐7 breast cancer cells induce secretion of VWF, angiopoietin‐2, and osteoprotegerin from ECs, which is further enhanced by the presence of platelets. Vascular endothelial growth factor‐A (VEGF‐A) plays an important role in modulating breast cancer‐induced VWF release. Moreover, VEGF‐A from breast tumor cells also contributes to a pro‐angiogenic effect on ECs. VWF multimers secreted from ECs, in response to tumor‐VEGF‐A, mediate adhesion of breast tumor cells along the endothelium. LMWH inhibits VWF‐breast tumor adhesion and transendothelial migration. Our findings highlight the significant crosstalk between tumor cells and the endothelium including increased VWF secretion which may contribute to tumor metastasis.

1 July 2009 in The Spine Journal
Verified
Journal Article
Closed access
WMWayne Murrell
Wayne Murrell
ESEmma Sanford
Emma Sanford
LALeif Anderberg
Leif Anderberg
BCBrenton Cavanagh
Brenton Cavanagh
AMAlan Mackay-Sim
Alan Mackay-Sim

1 September 2016 in Chem
Verified
Journal Article
Closed access
ESEsther M. Surender
Esther M. Surender
SCSteve Comby
Steve Comby
BCBrenton Cavanagh
Brenton Cavanagh
OBOrlaith Brennan
Orlaith Brennan
TLT. Clive Lee
T. Clive Lee
TGThorfinnur Gunnlaugsson
Thorfinnur Gunnlaugsson

1 April 2016 in Biomaterials
Verified
Journal Article
Closed access
Cian O'LearyCian O'Leary
Cian O'Leary
BCBrenton Cavanagh
Brenton Cavanagh
RURonald Unger
Ronald Unger
CKCharles James Kirkpatrick
Charles James Kirkpatrick
SOShirley O'DEa
Shirley O'DEa
SCSally-Ann Cryan
Sally-Ann Cryan